Current Flurizan™ Phase 3 Study Design May Demonstrate Disease Modification
Read the entire release at The Alzheimer's Reading Room
myriad genetics
"staggered start"
Alzheimer's Association Prevention Conference
disease modification
Flurizan Phase 3
Monday, June 11, 2007
Myriad Genetics (MYGN) Presents Mathematical Comparison of Disease Modification Trial Designs at Alzheimer's Conference
Subscribe to:
Posts (Atom)
